

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
16 June 2022 (16.06.2022)



(10) International Publication Number
WO 2022/125913 A1

(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 47/54 (2017.01)

(21) International Application Number:

PCT/US2021/062831

(22) International Filing Date:

10 December 2021 (10.12.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/124,581 11 December 2020 (11.12.2020) US
63/134,884 07 January 2021 (07.01.2021) US
63/178,340 22 April 2021 (22.04.2021) US
63/261,505 22 September 2021 (22.09.2021) US

(71) Applicant: **CIVI BIOPHARMA, INC.** [US/US]; 5425 Wisconsin Avenue, Chevy Chase, Maryland 20815 (US).

(72) Inventors: **OERUM, Henrik**; c/o Civi Biopharma, Inc., 5425 Wisconsin Avenue, Chevy Chase, Maryland 20815 (US). **NOBLE, Stewart Alwyn**; c/o Civi Biopharma, Inc., 5425 Wisconsin Avenue, Chevy Chase, Maryland 20815 (US). **SHEAR, Charles Lester**; c/o Civi Biopharma, Inc., 5425 Wisconsin Avenue, Chevy Chase, Maryland 20815 (US).

(74) Agent: **COVERT, John M.** et al.; STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9

(57) Abstract: The present disclosure provides pharmaceutical compositions for oral delivery comprising an antisense oligonucleotide (e.g., CIVI 008) and an oral delivery agent such as 5-CNAC. In some aspects, the disclosure provides a capsule comprising a dry blend of CIVI 008 and 5-CNAC, and optionally a statin.

WO 2022/125913 A1